^
Association details:
Biomarker:BRCA2 I2315T
Cancer:Pancreatic Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report

Published date:
01/06/2021
Excerpt:
Due to the novel nonsynonymous BRCA2 point mutation, we decided to change the strategy by administering olaparib. The patient benefited from olaparib therapy and achieved a PFS of ~ 6.5 months....We describe a patient carrying a novel somatic BRCA2 p. I2315T point mutation, which is first reported in metastatic pancreatic cancer.
DOI:
10.1186/s12920-020-00850-6